ClinicalTrials.gg

Program

SAL003

A development code. Also written as “SAL003 140 mg”, “SAL003 140mg+Atorvastatin” and “SAL003 420mg+Atorvastatin”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 3, since Nov 19, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals30 open or runningphase 3since Nov 19, 2025Nov 19, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2025First study: phase 3 study in HyperlipidemiasFirst studyNCT07253584 · 720 enrolled · China
  2. Dec 1, 2025Phase 2 study in HypercholesterolemiaNCT07278830 · 214 enrolled · China
  3. Dec 7, 2025Phase 3 study in HyperlipidemiasNCT07295418 · 618 enrolled · China

TargetBeta

PCSK9 →read by rule
“This is a Phase 3 study to evaluate the efficacy and safety of SAL003, a fully human monoclonal antibody against PCSK9, as monotherapy in Chinese participants with hypercholesterolemia and mixed dyslipidemia.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07295418Hyperlipidemias · China3CompletedApr 22, 2025618
NCT07278830Hypercholesterolemia · China2CompletedMay 24, 2024214
NCT07253584Hyperlipidemias · China3CompletedJun 23, 2025720

How it is read

Names in the registry

  • “SAL003 140 mg”, 2 entries
  • “SAL003 140mg+Atorvastatin”, 1 entry
  • “SAL003 420mg+Atorvastatin”, 1 entry

Codes read as this program: SAL003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.